Business Trip
61 episodes - English - Latest episode: 24 days ago -Business Trip tells the story of businesses at the frontier of mental health and wellness. Each episode features founders, investors, and researchers in psychedelics, neurotechnology, metabolic psychiatry, digital therapeutics, and more.
Homepage Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Analyzing the atai Life Sciences IPO
June 10, 2021 01:00 - 50 minutes - 34.5 MBToday's episode features three experts, Josh Hardman, Michael Haichin, and Graham Pechenik as they analyze atai’s S-1 in advance of their IPO. In this episode, we discuss: How atai went from idea to IPO in 3 years An overview of atai’s drug development programs and enabling technologies The platform’s strategy and risks Links to topics in this episode: Atai life sciences Etifoxine Esketamine & arketamine Atai’s S-1 Psychedelic Pharmacist Association Calyx Law Psilocybin Alpha, Noetic F...
A 30 year journey towards ibogaine approval: Deborah Mash, CEO of DemeRx
May 04, 2021 05:00 - 44 minutes - 30.8 MBToday's episode features Deborah Mash, founder and CEO of DemeRx, a clinical stage company developing ibogaine therapies to treat substance use disorders. In this episode, we discuss: The science, experience and the safety behind Ibogaine’s “neurochemical reset” Navigating US drug regulatory system and securing Intellectual Property Deborah’s 30 journey through Amsterdam, Miami and the Caribbean aiming to get Ibogaine therapy approved Partnership with ATAI Life Sciences Links to topics...
Clinical trials, media, reciprocity, open science: Founder of The Trip Report, Zach Haigney
March 16, 2021 21:00 - 21 minutes - 14.9 MBToday's episode features Zach Haigney, creator of The Trip Report, a newsletter about psychedelics, policy and business. In 2019, Zach started writing The Trip Report and quickly grew his readership by analyzing psychedelic news headlines from every angle. He’s able to break through all the noise and report with a sense of fairness. In this episode, we discuss: Origin story of The Trip Report The complexities of clinical trials Diversity, inclusion and reciprocity in psychedelic compani...
How to (legally) make psychedelic medicine: CEO of Psygen, Danny Motyka
February 24, 2021 16:00 - 30 minutes - 21.3 MBToday's episode features Danny Motyka, founder of Psygen, a Canadian manufacturer of psychedelics, like MDMA, LSD, DMT, and synthetic psilocybin. Psygen makes pharmaceutical grade psychedelic medicines for clinical research and therapeutic applications. They have a license to be one of the first manufacturing facilities dedicated to the synthesis of psychedelic medicine. In this episode, we discuss: Behind the scenes of Psygen’s manufacturing process Natural vs Synthetic psychedelics N...
From serving medicine to company founder: NANA founder Flor Bollini
January 05, 2021 02:00 - 33 minutes - 22.8 MBToday's episode features Flor Bollini, founder of NANA, an online platform that guides patients on using psychedelic medicine for holistic healing. NANA provides personalized protocols based on an assessment of your mental, emotional and physical health. From there you are partnered with a Nana or guide who leads telemedicine therapy that incorporates ketamine, cannabis and CBD. Flor hopes these protocols will become best practices for patients, clinics, and the psychedelic medicine ecosys...
Helping psychedelic practitioners through software: Maya Health CEO David Champion
October 19, 2020 06:00 - 29 minutes - 20.3 MBToday's episode features David Champion, CEO and co-founder of Maya, a software platform that helps practitioners and clinics manage psychedelic-assisted therapy practices. The data collected from treatments will help psychedelic stakeholders, from researchers to pharmaceutical companies, discover insights for safer and more effective treatments. In this episode, we discuss: Removing the guesswork from developing psychedelic therapy protocols Fundraising tips for psychedelic company found...
How to invest in psychedelic companies: Vine Ventures' Founder Ryan Zurrer
September 17, 2020 06:00 - 57 minutes - 39.3 MBToday's episode features Ryan Zurrer, founder of Vine Ventures, one of the first venture capital funds investing in psychedelic medicine. Ryan has deep roots in psychedelics culture and understands the many cultures within the psychedelic space. His fund is aligned with those values. If you’re a founder, investor, or early hire at a psychedelic company, this episode is a must-listen! In this episode, we discuss: Which psychedelic business models are a good fit for venture capital? Why di...
Vine Ventures' Founder Ryan Zurrer: How to invest in psychedelic companies
September 17, 2020 06:00 - 56 minutes - 39.1 MBToday's episode features Ryan Zurrer, founder of Vine Ventures, one of the first venture capital funds investing in psychedelic medicine. Ryan has deep roots in psychedelics culture and understands the many cultures within the psychedelic space. His fund is aligned with those values. If you’re a founder, investor, or early hire at a psychedelic company, this episode is a must-listen! In this episode, we discuss: Which psychedelic business models are a good fit for venture capital? Why di...
DoubleBlind's Shelby Hartman and Madison Margolin: Building a psychedelic media company
August 13, 2020 16:00 - 26 minutes - 18.4 MBToday’s episode features Shelby Hartman and Madison Margolin from DoubleBlind, a psychedelic magazine and media company founded in 2019 covering timely, untold stories about the expansion of psychedelics around the globe. Focused on how the industry can engage in sacred reciprocity and ethical psychedelic therapies, DoubleBlind is a for-profit company working on becoming a fully licensed certified B corporation. Links to topics discussed in this episode: What It’s Like to Have Sex on Differ...
Building a psychedelic media company: DoubleBlind's Shelby Hartman and Madison Margolin
August 13, 2020 16:00 - 26 minutes - 18.4 MBToday’s episode features Shelby Hartman and Madison Margolin from DoubleBlind, a psychedelic magazine and media company founded in 2019 covering timely, untold stories about the expansion of psychedelics around the globe. Focused on how the industry can engage in sacred reciprocity and ethical psychedelic therapies, DoubleBlind is a for-profit company working on becoming a fully licensed certified B corporation. Links to topics discussed in this episode: What It’s Like to Have Sex on Differ...
Dylan Beynon, CEO of Mindbloom: How ketamine-assisted therapy treats anxiety and depression
June 21, 2020 02:00 - 31 minutes - 21.6 MBToday’s episode features Dylan Beynon from Mindbloom, a mental and wellbeing startup that is currently offering ketamine-assisted therapy to treat anxiety and depression. Mindbloom is opening clinics across the country and is using technology to lower the cost of treatment. Host Greg Kubin participates in a ketamine-assisted therapy session in the episode. And that ethereal track you hear during the ketamine session is called Happiness Frequency by Conscious Sounds 432hz. Created by Greg ...